Factors affecting survival and recurrence in patients with operated non-small cell lung cancer

gülmez, ahmet; ELKIRAN, EMIN TAMER

doi:10.5455/annalsmedres.2022.12.373

Factors affecting survival and recurrence in patients with operated non-small cell lung cancer

Ahmet GÜLMEZ, (Adana Şehir Eğitim ve Araştırma Hastanesi, Tıbbi Onkoloji Kliniği, Adana, Türkiye)

Emin ELKIRAN (İnönü Üniversitesi, Tıp Fakültesi, Tıbbi Onkoloji Anabilim Dalı, Malatya, Türkiye)

Annals of Medical Research

1 0

Yıl: 2023 Cilt: 30 Sayı: 2 Sayfa Aralığı: 272 - 277 Metin Dili: İngilizce DOI: 10.5455/annalsmedres.2022.12.373 İndeks Tarihi: 05-04-2023

Factors affecting survival and recurrence in patients with operated non-small cell lung cancer

Öz:

Aim: The most serious problem after curative treatment of non-metastatic lung cancer is disease recurrence. This study was designed to detect markers affecting disease recurrence and survival in operated lung cancer patients. Materials and Methods: In this study, the data of 109 patients diagnosed with lung cancer were analyzed retrospectively. Cut-off values for neutrophil-lymphocyte ra- tio (NLR), platelet-lymphocyte ratio (PLR), alkaline phosphatase (ALP), and gamma glutamyl transpeptidase (GGT) were determined by performing ROC Curve analysis. Ac- cording to these cut-off values, the patients were divided into two groups. Based on the cut-off value of the markers, their effects on both overall survival (OS) and disease-free survival (DFS) were examined. Results: In this study, the median OS of the patients was 53.9 months, and the median DFS was 20.6 months. The patients were re-evaluated by targeting the cut-off value of 2.35 for NLR obtained by ROC analysis. Below this value, mOS and mDFS were calculated as 78.2 and 43.2 months, respectively. Above this value, it was determined as 35.6 and 20.6 months, respectively. A similar evaluation was made for the PLR. As a result of the ROC analysis, the cut-off value was determined as 124.7. Below this value, mOS and mDFS were calculated as 72.4 and 36.9 months, respectively. Above this value, it was determined as 41.7 and 21.8 months, respectively. Both results were statistically significant (p<0.05). Conclusion: This study showed that NLR and PLR predict statistical significance for OS and DFS.

Anahtar Kelime: Lung cancer Recurrence Survival Neutrophil-to-lymphocyte ratio Platelet-to-lymphocyte ratio

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of in- cidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2018;68(6):394-424.
2. Zhao Y, Varn FS, Cai G, Xiao F, Amos CI, Cheng C. A P53- Deficiency gene signature predicts recurrence risk of patients with early-stage lung adenocarcinoma. Cancer Epidemiology Biomarkers and Prevention. 2018;27(1):86-95.
3. Qiu B, Guo W, Zhang F, Lv F, Ji Y, Peng Y et al. Dy- namic recurrence risk and adjuvant chemotherapy benefit pre- diction by ctDNA in resected NSCLC. Nature Communications. 2021;12(1).
4. C.I. Diakos, K.A. Charles, D.C. McMillan, S.J. Clarke, Cancer- related inflammation and treatment effectiveness, Lancet On- col. 15 (2014) e493–e503, http://dx.doi. org/10.1016/S1470- 2045(14)70263-3.
5. A. Yuan, Y.-J. Hsiao, H.-Y. Chen, H.-W. Chen, C.-C. Ho, Y.- Y. Chen, et al., Opposite effects of M1 and M2 macrophage subtypes on lung cancer progression, Sci. Rep. 5 (2015) 14273.
6. H. Tao, Y. Mimura, K. Aoe, S. Kobayashi, H. Yamamoto, E. Matsuda, et al., Prognostic potential of FOXP3 expression in non-small cell lung cancer cells combined with tumor-infiltrating regulatory T cells, Lung Cancer 75 (2012) 95–101.
7. R.L. Stone, A.M. Nick, I.A. McNeish, F. Balkwill, H.D. Han, J. Bottsford-Miller, et al., Paraneoplastic thrombocytosis in ovar- ian cancer, N. Engl. J. Med. 366 (2012) 610–618.
8. Diem S, Schmid S, Krapf M, Flatz L, Born D, Jochum W et al. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to- Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. Lung Cancer. 2017 Sep;111:176-181.
9. Yamanaka T, Matsumoto S, Teramukai S, Ishiwata R, Nagai Y, Fukushima M. The baseline ratio of neutrophils to lymphocytes is associated with patient prognosis in advanced gastric cancer. Oncology 2007;73:215e20.
10. Shimada H, Takiguchi N, Kainuma O, Soda H, Ikeda A, Cho A, et al. High preoperative neutrophil-lymphocyte ratio predicts poor survival in patients with gastric cancer. Gastric Cancer 2010;13:170e6.
11. Jung MR, Park YK, Jeong O, Seon JW, Ryu SY, Kim DY, et al. Elevated preoperative neutrophil to lymphocyte ratio predicts poor survival following resection in late stage gastric cancer. J Surg Oncol 2011;104:504e10.
12. Chansky K, Detterbeck FC, Nicholson AG, Rusch VW, Vallières E, Groome P et al. The IASLC Lung Cancer Staging Project: External Validation of the Revision of the TNM Stage Groupings in the Eighth Edition of the TNM Classification of Lung Cancer. Journal of Thoracic Oncology. 2017;12(7):1109-1121.
13. Zhou Q, Su S, You W, Wang T, Ren T, Zhu L. Systemic Inflam- mation Response Index as a Prognostic Marker in Cancer Pa- tients: A Systematic Review and Meta-Analysis of 38 Cohorts. Dose-Response. 2021;19(4).
14. Winther-Larsen A, Aggerholm-Pedersen N, Sandfeld-Paulsen B. Inflammation-scores as prognostic markers of overall survival in lung cancer: a register-based study of 6,210 Danish lung cancer patients. BMC Cancer. 2022;22(1).
15. Mizuguchi S, Izumi N, Tsukioka T, Komatsu H, Nishiyama N. Neutrophil-lymphocyte ratio predicts recurrence in patients with resected stage 1 non-small cell lung cancer. J Cardiothorac Surg. 2018 27;13(1):78.
16. Li QG, Li P, Tang D, Chen J, Wang DR. Impact of postoperative complications on long-term survival after radical resection for gastric cancer. World J Gastroenterol 2013;19:4060e5.
17. Kubota T, Hiki N, Nunobe S, Kumagai K, Aikou S, Watanabe R, et al. Significance of the inflammation-based Glasgow prognostic score for short- and long-term outcomes after curative resection of gastric cancer. J Gastrointest Surg 2012;16:2037e44.
18. Chen Y, Chen K, Xiao X, Nie Y, Qu S, Gong C et al. Pretreat- ment neutrophil-to-lymphocyte ratio is correlated with response to neoadjuvant chemotherapy as an independent prognostic in- dicator in breast cancer patients: a retrospective study. BMC Cancer. 2016 19;16:320.
19. Bryant AK, Sankar K, Strohbehn GW, Zhao L, Elliott D, Qin A el al. Prognostic and predictive value of neutrophil-to- lymphocyte ratio with adjuvant immunotherapy in stage III non- small-cell lung cancer. Lung Cancer. 2022 ;163:35-41.
20. Toda M, Tsukioka T, Izumi N, Komatsu H, Okada S, Hara K et al. Platelet-to-lymphocyte ratio predicts the progno- sis of patients with non-small cell lung cancer treated with surgery and postoperative adjuvant chemotherapy. Thorac Can- cer. 2018;9(1):112-119.
21. Łochowski M, Chałubińska-Fendler J, Zawadzka I, Łochowska B, Rębowski M, Brzeziński D et al. The Prognostic Signifi- cance of Preoperative Platelet-to-Lymphocyte and Neutrophil- to-Lymphocyte Ratios in Patients Operated for Non-Small Cell Lung Cancer. Cancer Manag Res. 2021 9;13:7795-7802.
22. Toledano-Fonseca M, Teresa Cano M, Inga E, Gómez-España A, Guil-Luna S, García-Ortiz MV et al. The combination of neutrophil–lymphocyte ratio and platelet–lymphocyte ratio with liquid biopsy biomarkers improves prognosis prediction in metastatic pancreatic cancer. Cancers (Basel). 2021;13(6):1-17.
23. Chawla A, Huang TL, Ibrahim AM, Hardacre JM, Siegel C, et al. Pretherapy neutrophil to lymphocyte ratio and platelet to lymphocyte ratio do not predict survival in resectable pancreatic cancer. HPB (Oxford). 2018 May;20(5):398-404.
24. Jiang G, Chen S, Chen M. Exploration of IMDC model in pa- tients with metastatic renal cell carcinoma using targeted agents: a meta-analysis. Int Braz J Urol. 2020 May-Jun;46(3):328-340.
25. Heinrich D, Bruland O, Guise TA, Suzuki H, Sartor O. Al- kaline phosphatase in metastatic castration-resistant prostate cancer: Reassessment of an older biomarker. Future Oncology. 2018;14(24):2543-2556.
26. van der Doelen MJ, Stockhaus A, Ma Y, Mehra N, Yachnin J, Gerritsen WR et al. Early alkaline phosphatase dynamics as biomarker of survival in metastatic castration-resistant prostate cancer patients treated with radium-223. Eur J Nucl Med Mol Imaging. 2021 Sep;48(10):3325-3334.

APA	gülmez a, ELKIRAN E (2023). Factors affecting survival and recurrence in patients with operated non-small cell lung cancer. , 272 - 277. 10.5455/annalsmedres.2022.12.373
Chicago	gülmez ahmet,ELKIRAN EMIN TAMER Factors affecting survival and recurrence in patients with operated non-small cell lung cancer. (2023): 272 - 277. 10.5455/annalsmedres.2022.12.373
MLA	gülmez ahmet,ELKIRAN EMIN TAMER Factors affecting survival and recurrence in patients with operated non-small cell lung cancer. , 2023, ss.272 - 277. 10.5455/annalsmedres.2022.12.373
AMA	gülmez a,ELKIRAN E Factors affecting survival and recurrence in patients with operated non-small cell lung cancer. . 2023; 272 - 277. 10.5455/annalsmedres.2022.12.373
Vancouver	gülmez a,ELKIRAN E Factors affecting survival and recurrence in patients with operated non-small cell lung cancer. . 2023; 272 - 277. 10.5455/annalsmedres.2022.12.373
IEEE	gülmez a,ELKIRAN E "Factors affecting survival and recurrence in patients with operated non-small cell lung cancer." , ss.272 - 277, 2023. 10.5455/annalsmedres.2022.12.373
ISNAD	gülmez, ahmet - ELKIRAN, EMIN TAMER. "Factors affecting survival and recurrence in patients with operated non-small cell lung cancer". (2023), 272-277. https://doi.org/10.5455/annalsmedres.2022.12.373

APA	gülmez a, ELKIRAN E (2023). Factors affecting survival and recurrence in patients with operated non-small cell lung cancer. Annals of Medical Research, 30(2), 272 - 277. 10.5455/annalsmedres.2022.12.373
Chicago	gülmez ahmet,ELKIRAN EMIN TAMER Factors affecting survival and recurrence in patients with operated non-small cell lung cancer. Annals of Medical Research 30, no.2 (2023): 272 - 277. 10.5455/annalsmedres.2022.12.373
MLA	gülmez ahmet,ELKIRAN EMIN TAMER Factors affecting survival and recurrence in patients with operated non-small cell lung cancer. Annals of Medical Research, vol.30, no.2, 2023, ss.272 - 277. 10.5455/annalsmedres.2022.12.373
AMA	gülmez a,ELKIRAN E Factors affecting survival and recurrence in patients with operated non-small cell lung cancer. Annals of Medical Research. 2023; 30(2): 272 - 277. 10.5455/annalsmedres.2022.12.373
Vancouver	gülmez a,ELKIRAN E Factors affecting survival and recurrence in patients with operated non-small cell lung cancer. Annals of Medical Research. 2023; 30(2): 272 - 277. 10.5455/annalsmedres.2022.12.373
IEEE	gülmez a,ELKIRAN E "Factors affecting survival and recurrence in patients with operated non-small cell lung cancer." Annals of Medical Research, 30, ss.272 - 277, 2023. 10.5455/annalsmedres.2022.12.373
ISNAD	gülmez, ahmet - ELKIRAN, EMIN TAMER. "Factors affecting survival and recurrence in patients with operated non-small cell lung cancer". Annals of Medical Research 30/2 (2023), 272-277. https://doi.org/10.5455/annalsmedres.2022.12.373